Skip to main content
OpenTrials
Completed

NCT Number: NCT02562079

Vasculopathy, Inflammation and Systemic Sclerosis

It is a study of basic research with mechanistically objectives and including clinical biological samples.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Service de Rhumatologie - Tripode - Hôpital Pellegrin

Bordeaux, 33076, France

About this study

Systemic sclerosis (SSc) is a rare and severe disease characterised by a fibrotic process and an incompletely elucidate physiopathology. Several shared featured have been identified between SSc and another autoimmune disease, the systemic lupus erythematous (SLE) as an interferon-alpha signature, the role of platelets and the polymorphism of OX40 ligand (OX40L). In SLE, OX40L has been shown highly linked to the active form of the disease, was increased by the CD40L of platelets and induced the CD8 cytotoxicity while inhibiting the suppressive functions of regulator T lymphocytes. The third main factor of the SSc physiopathology apart from autoimmunity and fibrosis is the vasculopathy with an important role of endothelial cells (EC). They turned out to be half-professional antigen presenting cells and can modulate the adaptive immunity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age from 18 to 75.
  • SSc diagnosed according to the American College of Rheumatology (ACR) criteria.
  • With skin manifestations since less than 10 years.
  • Localised sclerosis (LSc) diagnosed, morphea type.

Exclusion criteria

  • Age inferior to 18 or upper than 75.
  • Skin manifestations since more than 10 years.
  • Haemostasis diseases (independent from treatments).
  • Stem cell transplant.
  • Immunosuppressive treatments in the last 6 months.
  • Associate autoimmune disease.

Treatment and study plan

blood samples

Biological
  • biological features of the standard follow-up
  • 2 more blood tube for the biological collection (serum and PBMC)

Biopsy

Biological

Skin biopsies

Primary outcomes

  1. Assessment of OX40L expression in endothelial cells and skin biopsies.

    Time frame: Day 1

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Collaborators

  • Societe Francaise de Rhumatologie

Registry information

Official study title

Vasculopathy, Inflammation and Systemic Sclerosis: The Role of Endothelial Cell Activation and OX40/OX40L in Modulation of T Lymphocyte Activation

Acronym: VISS

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Sep 29, 2015
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.